Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
149.4 ^USD	-1.20%		-0.71%	-21.95%

May. 07	HC Wainwright Adjusts Price Target on Alnylam Pharmaceuticals to $400 From $395, Maintains Buy Rating	MT
May. 02	Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed	MT

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

May 02, 2024 at 08:00 am EDT

Alnylam Pharmaceuticals, Inc. reiterated earnings guidance for the full year 2024. For the period, the company expects combined net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO to be $1,400 million to $1,500 million and net revenues from collaborations and royalties to be $325 million to $425 million.

Latest news about Alnylam Pharmaceuticals, Inc.

HC Wainwright Adjusts Price Target on Alnylam Pharmaceuticals to $400 From $395, Maintains Buy Rating	May. 07	MT
Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed	May. 02	MT
Transcript : Alnylam Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024	May. 02
Earnings Flash (ALNY) ALNYLAM PHARMACEUTICALS Posts Q1 Revenue $494.3M, vs. Street Est of $426.9M	May. 02	MT
Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024	May. 02	CI
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of Their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in Additional Latam and APAC Markets Including Australia	Apr. 30	CI
Sector Update: Health Care Stocks Flat to Higher Premarket Monday	Apr. 08	MT
Sector Update: Health Care	Apr. 08	MT
Alnylam Pharmaceuticals Says Phase 2 Trial for Zilebesiran Meets Primary Endpoint	Apr. 08	MT
ANALYST RECOMMENDATIONS : Chevron, Take-Two, Coinbase, Netflix, American Tower...	Apr. 08
Transcript : Alnylam Pharmaceuticals, Inc. - Special Call	Apr. 07
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension	Apr. 07	CI
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Canaccord Genuity ?Genetic Medicine for Generalists?, Mar-25-2024 01:00 PM	Mar. 25
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Stifel Virtual 2024 CNS Day, Mar-20-2024 10:00 AM	Mar. 20
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:15 AM	Mar. 12
Alnylam Pharmaceuticals Says Phase 2 Study of Hypertension Drug Zilebesiran Meets Primary Endpoint	Mar. 05	MT
Transcript : Alnylam Pharmaceuticals, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 09:10 AM	Mar. 05
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran Is Added to Standard of Care Antihypertensives	Mar. 05	CI
Alnylam Pharmaceuticals Insider Sold Shares Worth $4,540,071, According to a Recent SEC Filing	Mar. 01	MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $455,357, According to a Recent SEC Filing	Feb. 29	MT
How long will this bullish phase last?	Feb. 26
ANALYST RECOMMENDATIONS : AbbVie, Doordash, Eli Lilly, Moderna, Hiscox...	Feb. 26
ANALYST RECOMMENDATIONS : Airbnb, Conagra Brands, Berkshire Hathaway, Meta Platforms, Unilever....	Feb. 21
North American Morning Briefing : Earnings Back in -2-	Feb. 20	DJ

Chart Alnylam Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Companyâs lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

Sector

Biotechnology & Medical Research

Calendar

2024-07-30 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Alnylam Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

149.4 USD

Average target price

220.4 USD

Spread / Average Target

+47.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
BIO-TECHNE CORPORATION	+8.61%	13.21B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-6.26%	11.42B

Other Biotechnology & Medical Research